Review Article
Challenges in Emerging Vaccines and Future Promising Candidates against SARS-CoV-2 Variants
Table 5
List of some COVID-19 vaccines under phase-3 clinical trials.
| Vaccine name and developer | Country | Type | Total number of trials | Number of countries approved for use |
| COVAXIN-Bharat Biotech | India | Inactivated | 16 | 14 | Coronavac-Sinovac | China | Inactivated | 42 | 56 | Sputnik Light—Gamaleya | Russia | Viral vector—nonreplicating | 7 | 26 | Oxford-AstraZeneca (Vaxzevria) | United Kingdom–Sweeden | Viral vector—nonreplicating | 73 | 149 | Serum Institute of India Covishield (Oxford/ AstraZeneca formulation) | India | Viral vector—nonreplicating | 6 | 49 | Sanofi/GSK VidPrevtyn beta | United States–Germany | Protein subunit | 3 | 30 | Novavax | Australia | Protein subunit | 22 | 40 | Recombinant COVID-19 Vaccine National Vaccine and Serum Institute | China | Protein subunit | 3 | 1 | Moderna mRNA-1273.214 | United States of America | RNA | 5 | 38 | Pfizer/BioNTech Comirnaty (BNT162b2) | | RNA | 100 | 149 |
|
|